胶质母细胞瘤（GBM）治疗的现状和未来治疗前景：综述。
Biomedicine & Pharmacotherapy
(
IF
6.9
)
Pub Date : 2017-06-06
, DOI:
10.1016/j.biopha.2017.05.125
Komal Anjum
1
,
Bibi Ibtesam Shagufta
2
,
Syed Qamar Abbas
3
,
Seema Patel
4
,
Ishrat Khan
1
,
Sayed Asmat Ali Shah
1
,
Najeeb Akhter
1
,
Syed Shams Ul Hassan
5
Affiliation
Ocean College, Zhejiang University, Hangzhou, 310058, China.
Department of Zoology, Kohat University of Science and Technology (KUST), K.P.K 26000, Pakistan.
Faculty of Pharmacy, Gomal University D.I.Khan, K.P.K 29050, Pakistan.
Bioinformatics and Medical Informatics Research Center, San Diego State University, San Diego-92182, USA.
College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China.
多形胶质母细胞瘤（GBM）是异源性脑癌的最致命形式。每年都会影响到大量患者，生存期约为8到15个月。GBM受复杂的信号通路驱动，被认为是最具挑战性的治疗方法。GBM的标准治疗包括手术，放射疗法，化学疗法以及综合治疗。这篇综述文章描述了GMB的肿瘤内和肿瘤内异质性。另外，已经定义了最近的化学治疗剂及其作用机理。FDA批准的药物也聚焦于此，最重要的是突出了一些天然和合成的新型抗神经胶质瘤药物，这些药物是当今研究人员的主要研究重点。
"点击查看英文标题和摘要"
Current status and future therapeutic perspectives of glioblastoma multiforme (GBM) therapy: A review.
Glioblastoma multiforme (GBM) is the deadliest form of heterogeneous brain cancer. It affects an enormous number of patients every year and the survival is approximately 8 to 15 months. GBM has driven by complex signaling pathways and considered as a most challenging to treat. Standard treatment of GBM includes surgery, radiation therapy, chemotherapy and also the combined treatment. This review article described inter and intra- tumor heterogeneity of GMB. In addition, recent chemotherapeutic agents, with their mechanism of action have been defined. FDA-approved drugs also been focused over here and most importantly highlighting some natural and synthetic and novel anti- glioma agents, that are the main focus of researchers nowadays.
